Keywords: Novo Nordisk, Victoza, Cardiovascular outcomes, Diabetes
Novo Nordisk partners with international scientific community for Victoza cardiovascular outcomes trial
Article | 07 May 2010
Danish insulin giant Novo Nordisk yesterday announced details of its cardiovascular outcomes trial for the type 2 diabetes agent Victoza (liraglutide [ ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Elan makes "transformational" acquisitions and a divestment
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- SciClone gains China rights to Zensun's Neucardin
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
